Exploratory analysis from POSEIDON Phase III
trial also showed trends for overall survival benefit with a
limited course of tremelimumab added to IMFINZI and chemotherapy in
subgroups with high unmet need
Updated results after approximately four years of follow-up of
the POSEIDON Phase III trial showed a limited course of
tremelimumab when added to AstraZeneca’s IMFINZI® (durvalumab) plus
four cycles of chemotherapy demonstrated a sustained improvement in
overall survival (OS) compared to chemotherapy alone in the
1st-line treatment of patients with Stage IV (metastatic) non-small
cell lung cancer (NSCLC). Additional post-hoc, exploratory analyses
continued to show a trend for OS improvement with this combination
in patients with STK11, KEAP1 and KRAS-mutated NSCLC, as well as in
patients whose tumors were PD-L1-negative (less than 1% tumor cell
expression).
These late-breaking results were presented today at the European
Society of Medical Oncology (ESMO) Congress 2022 (Abstract
#LBA59).
KRAS mutations are the most common tumor growth driver in NSCLC,
occurring in approximately 25% of patients. NSCLC tumors with STK11
and KEAP1 mutations are often associated with poor outcomes and
classified as immunologically “cold.” KRAS-mutated NSCLC can be
responsive to immunotherapy but also can have poor outcomes,
particularly when associated with STK11 or KEAP1
co-mutations.1-6
Melissa Johnson, MD, Director of Lung Cancer Research, Sarah
Cannon Research Institute at Tennessee Oncology in Nashville,
Tennessee, and a lead investigator in the POSEIDON Phase III trial,
said: "Metastatic non-small cell lung cancer is a devastating
diagnosis, particularly for patients whose cancers are less
responsive to standard treatments such as chemotherapy and immune
therapy. These results support the addition of a limited course of
tremelimumab to durvalumab plus chemotherapy as a potential new
treatment option for patients with these harder-to-treat forms of
lung cancer.”
Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca, said: "These updated POSEIDON results at nearly four
years of follow-up show further evidence that the addition of a
limited course of tremelimumab to IMFINZI plus chemotherapy
improves outcomes for metastatic non-small cell lung cancer
patients, including those with specific tumor mutations where a
high unmet need for effective, well tolerated treatments remains.
We look forward to bringing this potential new treatment option to
patients as quickly as possible."
These latest data show that a limited course of five cycles of
tremelimumab added to IMFINZI plus platinum-based chemotherapy
improved overall survival by 25% compared to chemotherapy alone
(hazard ratio [HR] 0.75; 95% CI 0.63-0.88). Updated median OS was
14 months for the combination versus 11.7 for chemotherapy alone.
An estimated 25% of patients treated with the combination were
alive at three years versus 13.6% for those treated with
chemotherapy alone.
A trend for OS improvement continued to be observed in patients
with STK11, KEAP1, and KRAS-mutated mNSCLC when treated with the
combination, which reduced the risk of death by 38% (based on a HR
of 0.62; 95% CI 0.34-1.12), 57% (based on a HR of 0.43; 95% CI
0.16-1.25), and 45% (based on a HR of 0.55; 95% CI 0.36-0.85),
respectively. The combination also extended sustained OS benefit to
patients with less than 1% PD-L1 tumor cell expression. These post
hoc, exploratory subgroup analyses should be interpreted with
caution due to the small sample sizes.
Consistent with previous POSEIDON Phase III trial readouts, OS
benefit in these updated results appeared more pronounced with
tremelimumab plus IMFINZI and chemotherapy in patients with
non-squamous NSCLC histology. A 32% improvement in OS compared to
chemotherapy alone (HR 0.68; 95% CI 0.55–0.85) was reported for
patients with non-squamous histology, with an updated median OS of
17.2 months for the combination versus 13.1 months for
chemotherapy. An estimated 31.4% of patients with non-squamous
NSCLC treated with the combination were alive at three years versus
17.3% for those receiving chemotherapy alone.
Summary of efficacy resultsi, ii
Tremelimumab + IMFINZI
+ chemotherapy
Chemotherapy
Intention-To-Treat (ITT)
n=338
n=337
Median OS (in months)
14.0
11.7
Hazard ratio (95% CI)iii
0.75 (0.63, 0.88)
OS rate at 3 years (%)
25.0
13.6
STK11 mutation
n=31
n=22
Median OS (in months)
15.0
10.7
Hazard ratio (95% CI)iv
0.62 (0.34, 1.12)
OS rate at 3 years (%)
25.8
4.5
KEAP1 mutation
n=22
n=6
Median OS (in months)
13.7
8.7
Hazard ratio (95% CI)iv
0.43 (0.16, 1.25)
OS rate at 3 years (%)
30.0
0.0
KRAS mutation
n=60
n=53
Median OS (in months)
25.7
10.4
Hazard ratio (95% CI)iv
0.55 (0.36, 0.85)
OS rate at 3 years (%)
40.0
15.8
i.
STK11 and KRAS subgroup analyses were
presented for patients with non-squamous histology; while the KEAP1
subgroup analysis was presented for all mutation-evaluable patients
irrespective of tumor histology, due to a small sample size.
ii.
Data cut-off (DCO) date: 11 March 2022.
Median follow-up in censored patients at DCO: 46.5 months (range
0.0–56.5)
iii.
Stratified analysis by PD-L1 expression
(TC ≥50% vs <50%), disease stage (IVA vs IVB) and histology
iv.
Unstratified analysis
Tremelimumab plus IMFINZI and chemotherapy continued to be
well-tolerated, with no new safety signals identified based on the
collection of serious adverse events (AEs) during the approximately
four-years of follow-up. Serious treatment-related AEs of any grade
occurred in 27.6% of patients in the IMFINZI, tremelimumab and
chemotherapy arm versus 17.7% in the chemotherapy alone arm as
assessed by investigators. Treatment-related AEs leading to death
occurred in 3.3% of patients in the combination arm versus 2.4% in
the chemotherapy arm.
These updated results build on the primary progression-free
survival (PFS) and OS results presented at the 2021 World
Conference on Lung Cancer (WCLC) in September 2021 as well as
post-hoc exploratory results in patients with STK11, KEAP1 or
KRAS-mutated metastatic NSCLC recently presented at WCLC 2022 in
August.
Tremelimumab is under review by global regulatory authorities in
combination with IMFINZI and chemotherapy in 1st-line metastatic
NSCLC based on the results of the POSEIDON trial.
IMPORTANT SAFETY INFORMATION
There are no contraindications for IMFINZI® (durvalumab).
Immune-Mediated Adverse Reactions
Important immune-mediated adverse reactions listed under
Warnings and Precautions may not include all possible severe and
fatal immune-mediated reactions. Immune-mediated adverse reactions,
which may be severe or fatal, can occur in any organ system or
tissue. Immune-mediated adverse reactions can occur at any time
after starting treatment or after discontinuation. Monitor patients
closely for symptoms and signs that may be clinical manifestations
of underlying immune-mediated adverse reactions. Evaluate liver
enzymes, creatinine, and thyroid function at baseline and
periodically during treatment. In cases of suspected
immune-mediated adverse reactions, initiate appropriate workup to
exclude alternative etiologies, including infection. Institute
medical management promptly, including specialty consultation as
appropriate. Withhold or permanently discontinue IMFINZI depending
on severity. See Dosing and Administration for specific details. In
general, if IMFINZI requires interruption or discontinuation,
administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day
prednisone or equivalent) until improvement to Grade 1 or less.
Upon improvement to Grade 1 or less, initiate corticosteroid taper
and continue to taper over at least 1 month. Consider
administration of other systemic immunosuppressants in patients
whose immune-mediated adverse reactions are not controlled with
corticosteroid therapy.
Immune-Mediated Pneumonitis
IMFINZI can cause immune-mediated pneumonitis. The incidence of
pneumonitis is higher in patients who have received prior thoracic
radiation. In patients who did not receive recent prior radiation,
the incidence of immune-mediated pneumonitis was 2.4% (34/1414),
including fatal (<0.1%), and Grade 3-4 (0.4%) adverse reactions.
In patients who received recent prior radiation, the incidence of
pneumonitis (including radiation pneumonitis) in patients with
unresectable Stage III NSCLC following definitive chemoradiation
within 42 days prior to initiation of IMFINZI in PACIFIC was 18.3%
(87/475) in patients receiving IMFINZI and 12.8% (30/234) in
patients receiving placebo. Of the patients who received IMFINZI
(475), 1.1% were fatal and 2.7% were Grade 3 adverse reactions. The
frequency and severity of immune-mediated pneumonitis in patients
who did not receive definitive chemoradiation prior to IMFINZI were
similar in patients who received IMFINZI as a single agent or with
ES-SCLC when in combination with chemotherapy.
Immune-Mediated Colitis
IMFINZI can cause immune-mediated colitis that is frequently
associated with diarrhea. Cytomegalovirus (CMV)
infection/reactivation has been reported in patients with
corticosteroid-refractory immune-mediated colitis. In cases of
corticosteroid-refractory colitis, consider repeating infectious
workup to exclude alternative etiologies. Immune-mediated colitis
occurred in 2% (37/1889) of patients receiving IMFINZI, including
Grade 4 (<0.1%) and Grade 3 (0.4%) adverse reactions.
Immune-Mediated Hepatitis
IMFINZI can cause immune-mediated hepatitis. Immune-mediated
hepatitis occurred in 2.8% (52/1889) of patients receiving IMFINZI,
including fatal (0.2%), Grade 4 (0.3%) and Grade 3 (1.4%) adverse
reactions.
Immune-Mediated Endocrinopathies
- Adrenal Insufficiency: IMFINZI can cause primary
or secondary adrenal insufficiency. For Grade 2 or higher adrenal
insufficiency, initiate symptomatic treatment, including hormone
replacement as clinically indicated. Immune-mediated adrenal
insufficiency occurred in 0.5% (9/1889) of patients receiving
IMFINZI, including Grade 3 (<0.1%) adverse reactions.
- Hypophysitis: IMFINZI can cause immune-mediated
hypophysitis. Hypophysitis can present with acute symptoms
associated with mass effect such as headache, photophobia, or
visual field cuts. Hypophysitis can cause hypopituitarism. Initiate
symptomatic treatment including hormone replacement as clinically
indicated. Grade 3 hypophysitis/hypopituitarism occurred in
<0.1% (1/1889) of patients who received IMFINZI.
- Thyroid Disorders: IMFINZI can cause
immune-mediated thyroid disorders. Thyroiditis can present with or
without endocrinopathy. Hypothyroidism can follow hyperthyroidism.
Initiate hormone replacement therapy for hypothyroidism or
institute medical management of hyperthyroidism as clinically
indicated.
- Thyroiditis: Immune-mediated thyroiditis occurred
in 0.5% (9/1889) of patients receiving IMFINZI, including Grade 3
(<0.1%) adverse reactions.
- Hyperthyroidism: Immune-mediated hyperthyroidism
occurred in 2.1% (39/1889) of patients receiving IMFINZI.
- Hypothyroidism: Immune-mediated hypothyroidism
occurred in 8.3% (156/1889) of patients receiving IMFINZI,
including Grade 3 (<0.1%) adverse reactions.
- Type 1 Diabetes Mellitus, which can present with diabetic
ketoacidosis: Monitor patients for hyperglycemia or
other signs and symptoms of diabetes. Initiate treatment with
insulin as clinically indicated. Grade 3 immune-mediated type 1
diabetes mellitus occurred in <0.1% (1/1889) of patients
receiving IMFINZI.
Immune-Mediated Nephritis with Renal Dysfunction
IMFINZI can cause immune-mediated nephritis. Immune-mediated
nephritis occurred in 0.5% (10/1889) of patients receiving IMFINZI,
including Grade 3 (<0.1%) adverse reactions.
Immune-Mediated Dermatology Reactions
IMFINZI can cause immune-mediated rash or dermatitis.
Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS),
drug rash with eosinophilia and systemic symptoms (DRESS), and
toxic epidermal necrolysis (TEN), have occurred with PD-1/L-1
blocking antibodies. Topical emollients and/or topical
corticosteroids may be adequate to treat mild to moderate
non-exfoliative rashes. Immune-mediated rash or dermatitis occurred
in 1.8% (34/1889) of patients receiving IMFINZI, including Grade 3
(0.4%) adverse reactions.
Other Immune-Mediated Adverse Reactions
The following clinically significant, immune-mediated adverse
reactions occurred at an incidence of less than 1% each in patients
who received IMFINZI or were reported with the use of other
PD-1/PD-L1 blocking antibodies.
- Cardiac/vascular: Myocarditis, pericarditis,
vasculitis.
- Nervous system: Meningitis, encephalitis, myelitis and
demyelination, myasthenic syndrome/myasthenia gravis (including
exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune
neuropathy.
- Ocular: Uveitis, iritis, and other ocular inflammatory
toxicities can occur. Some cases can be associated with retinal
detachment. Various grades of visual impairment to include
blindness can occur. If uveitis occurs in combination with other
immune-mediated adverse reactions, consider a
Vogt-Koyanagi-Harada-like syndrome, as this may require treatment
with systemic steroids to reduce the risk of permanent vision
loss.
- Gastrointestinal: Pancreatitis including increases in
serum amylase and lipase levels, gastritis, duodenitis.
- Musculoskeletal and connective tissue disorders:
Myositis/polymyositis, rhabdomyolysis and associated sequelae
including renal failure, arthritis, polymyalgia rheumatic.
- Endocrine: Hypoparathyroidism
- Other (hematologic/immune): Hemolytic anemia, aplastic
anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory
response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi
lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ
transplant rejection.
Infusion-Related Reactions
IMFINZI can cause severe or life-threatening infusion-related
reactions. Monitor for signs and symptoms of infusion-related
reactions. Interrupt, slow the rate of, or permanently discontinue
IMFINZI based on the severity. See Dosing and Administration for
specific details. For Grade 1 or 2 infusion-related reactions,
consider using pre-medications with subsequent doses.
Infusion-related reactions occurred in 2.2% (42/1889) of patients
receiving IMFINZI, including Grade 3 (0.3%) adverse reactions.
Complications of Allogeneic HSCT after IMFINZI
Fatal and other serious complications can occur in patients who
receive allogeneic hematopoietic stem cell transplantation (HSCT)
before or after being treated with a PD-1/L-1 blocking antibody.
Transplant-related complications include hyperacute
graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic
veno-occlusive disease (VOD) after reduced intensity conditioning,
and steroid-requiring febrile syndrome (without an identified
infectious cause). These complications may occur despite
intervening therapy between PD-1/L-1 blockade and allogeneic HSCT.
Follow patients closely for evidence of transplant-related
complications and intervene promptly. Consider the benefit versus
risks of treatment with a PD-1/L-1 blocking antibody prior to or
after an allogeneic HSCT.
Embryo-Fetal Toxicity
Based on its mechanism of action and data from animal studies,
IMFINZI can cause fetal harm when administered to a pregnant woman.
Advise pregnant women of the potential risk to a fetus. Advise
females of reproductive potential to use effective contraception
during treatment with IMFINZI and for at least 3 months after the
last dose of IMFINZI.
Lactation
There is no information regarding the presence of IMFINZI in
human milk; however, because of the potential for adverse reactions
in breastfed infants from IMFINZI, advise women not to breastfeed
during treatment and for at least 3 months after the last dose.
Adverse Reactions
- In patients with Stage III NSCLC in the PACIFIC study receiving
IMFINZI (n=475), the most common adverse reactions (≥20%) were
cough (40%), fatigue (34%), pneumonitis or radiation pneumonitis
(34%), upper respiratory tract infections (26%), dyspnea (25%), and
rash (23%). The most common Grade 3 or 4 adverse reactions (≥3%)
were pneumonitis/radiation pneumonitis (3.4%) and pneumonia
(7%)
- In patients with Stage III NSCLC in the PACIFIC study receiving
IMFINZI (n=475), discontinuation due to adverse reactions occurred
in 15% of patients in the IMFINZI arm. Serious adverse reactions
occurred in 29% of patients receiving IMFINZI. The most frequent
serious adverse reactions (≥2%) were pneumonitis or radiation
pneumonitis (7%) and pneumonia (6%). Fatal pneumonitis or radiation
pneumonitis and fatal pneumonia occurred in <2% of patients and
were similar across arms
- In patients with extensive-stage SCLC in the CASPIAN study
receiving IMFINZI plus chemotherapy (n=265), the most common
adverse reactions (≥20%) were nausea (34%), fatigue/asthenia (32%),
and alopecia (31%). The most common Grade 3 or 4 adverse reaction
(≥3%) was fatigue/asthenia (3.4%)
- In patients with extensive-stage SCLC in the CASPIAN study
receiving IMFINZI plus chemotherapy (n=265), IMFINZI was
discontinued due to adverse reactions in 7% of the patients
receiving IMFINZI plus chemotherapy. Serious adverse reactions
occurred in 31% of patients receiving IMFINZI plus chemotherapy.
The most frequent serious adverse reactions reported in at least 1%
of patients were febrile neutropenia (4.5%), pneumonia (2.3%),
anemia (1.9%), pancytopenia (1.5%), pneumonitis (1.1%), and COPD
(1.1%). Fatal adverse reactions occurred in 4.9% of patients
receiving IMFINZI plus chemotherapy
The safety and effectiveness of IMFINZI have not been
established in pediatric patients.
Indications:
IMFINZI is indicated for the treatment of adult patients with
unresectable Stage III non-small cell lung cancer (NSCLC) whose
disease has not progressed following concurrent platinum-based
chemotherapy and radiation therapy.
IMFINZI, in combination with etoposide and either carboplatin or
cisplatin, is indicated for the first-line treatment of adult
patients with extensive-stage small cell lung cancer (ES-SCLC).
Please see complete Prescribing Information, including
Medication Guide.
Notes
Stage IV NSCLC
Lung cancer is broadly split into NSCLC and small cell lung
cancer (SCLC), with 80-85% classified as NSCLC. 7-9 Within NSCLC,
patients are classified as squamous, representing 25-30% of
patients, or non-squamous, the most common type representing
approximately 70-75% of NSCLC patients.7 Stage IV is the most
advanced form of lung cancer and is often referred to as metastatic
disease.10 Approximately 5% of patients with metastatic NSCLC will
survive 5 years after diagnosis.11
POSEIDON
The POSEIDON trial was a randomized, open-label, multi-center,
global, Phase III trial of IMFINZI plus platinum-based chemotherapy
or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone
in the 1st-line treatment of 1,013 patients with metastatic NSCLC.
The trial population included patients with either non-squamous or
squamous disease and the full range of PD-L1 expression levels.
POSEIDON excluded patients with certain epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK)
fusions.
In the experimental arms, patients were treated with a flat dose
of 1,500mg of IMFINZI, or IMFINZI and 75mg of tremelimumab with up
to four cycles of chemotherapy every three weeks, followed by
maintenance treatment with IMFINZI once every four weeks, or
IMFINZI and a fifth dose of 75mg of tremelimumab given at week 16.
In comparison, the control arm allowed up to six cycles of
chemotherapy. Pemetrexed maintenance treatment was allowed in all
arms in patients with non-squamous disease if given during the
induction phase. Nearly all patients with non-squamous disease
(95.5%) had pemetrexed and platinum, while the majority of patients
with squamous disease receiving chemotherapy (88.3%) received
gemcitabine and platinum.
Primary endpoints included PFS and OS for the IMFINZI plus
chemotherapy arm. Key secondary endpoints included PFS and OS in
the IMFINZI plus tremelimumab and chemotherapy arm. As both PFS
endpoints were met for IMFINZI plus chemotherapy and IMFINZI,
tremelimumab and chemotherapy, the prespecified statistical
analysis plan allowed for testing OS in the IMFINZI plus
tremelimumab and chemotherapy arm. The trial was conducted in more
than 150 centers across 18 countries, including the US, Europe,
South America, Asia and South Africa.
IMFINZI®
IMFINZI (durvalumab) is a human monoclonal antibody that binds
to the PD-L1 protein and blocks the interaction of PD-L1 with the
PD-1 and CD80 proteins, countering the tumor's immune-evading
tactics and releasing the inhibition of immune responses.
IMFINZI is the only approved immunotherapy in the
curative-intent setting of unresectable, Stage III non-small cell
lung cancer (NSCLC) in patients whose disease has not progressed
after chemoradiotherapy, and is the global standard of care in this
setting based on the PACIFIC Phase III trial.
IMFINZI is currently approved in a number of countries in
multiple tumor types including for the treatment of extensive-stage
small cell lung cancer (ES-SCLC); for previously treated patients
with advanced bladder cancer and for locally advanced or metastatic
BTC in combination with chemotherapy (gemcitabine plus
cisplatin).
Since the first approval in May 2017, more than 100,000 patients
have been treated with IMFINZI.
IMFINZI combinations have demonstrated clinical benefit in
multiple additional cancer settings with positive Phase III trials
in unresectable advanced liver cancer (HIMALAYA), metastatic NSCLC
(POSEIDON) and resectable NSCLC (AEGEAN). The data from HIMALAYA
and POSEIDON are under review with global health authorities.
As part of a broad development program, IMFINZI is being tested
as a single treatment and in combinations with other anti-cancer
treatments for patients with SCLC, NSCLC, bladder cancer, several
GI cancers, ovarian cancer, endometrial cancer and other solid
tumors.
Tremelimumab
Tremelimumab is a human monoclonal antibody and potential new
medicine that targets the activity of cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab blocks the
activity of CTLA-4, contributing to T-cell activation, priming the
immune response to cancer and fostering cancer cell death.
Beyond POSEIDON, tremelimumab is being tested in combination
with IMFINZI across multiple tumor types including in bladder
cancer (VOLGA and NILE), locoregional HCC (EMERALD-3) and SCLC
(ADRIATIC).
Tremelimumab is also under review by global regulatory
authorities in combination with IMFINZI in unresectable advanced
liver cancer based on the results of the HIMALAYA Phase III
trial.
AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer
to cure through the detection and treatment of early-stage disease,
while also pushing the boundaries of science to improve outcomes in
the resistant and advanced settings. By defining new therapeutic
targets and investigating innovative approaches, the Company aims
to match medicines to the patients who can benefit most.
The Company’s comprehensive portfolio includes leading lung
cancer medicines and the next wave of innovations including
osimertinib; durvalumab and tremelimumab; fam-trastuzumab
deruxtecan-nxki and datopotamab deruxtecan in collaboration with
Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well
as a pipeline of potential new medicines and combinations across
diverse mechanisms of action.
AstraZeneca is a founding member of the Lung Ambition Alliance,
a global coalition working to accelerate innovation and deliver
meaningful improvements for people with lung cancer, including and
beyond treatment.
AstraZeneca in immuno-oncology (IO)
Immunotherapy is a therapeutic approach designed to stimulate
the body’s immune system to attack tumors. The Company’s
Immuno-Oncology (IO) portfolio is anchored in immunotherapies that
have been designed to overcome evasion of the anti-tumor immune
response. AstraZeneca is invested in using IO approaches that
deliver long-term survival for new groups of patients across tumor
types.
The Company is pursuing a comprehensive clinical-trial program
that includes IMFINZI as a single treatment and in combination with
tremelimumab and other novel antibodies in multiple tumor types,
stages of disease, and lines of treatment, and where relevant using
the PD-L1 biomarker as a decision-making tool to define the best
potential treatment path for a patient.
In addition, the ability to combine the IO portfolio with
radiation, chemotherapy, and targeted small molecules from across
AstraZeneca’s oncology pipeline, and from research partners, may
provide new treatment options across a broad range of tumors.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyze changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development, and commercialization
of prescription medicines in Oncology, Rare Diseases, and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge,
UK, AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more
information, please visit www.astrazeneca-us.com and follow us on
Twitter @AstraZenecaUS.
US- 68343 Last Updated 9/22
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220911005050/en/
Media Inquiries Brendan McEvoy,+1 302 885 2677 Jessica
McDuell, +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024